By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Yamanouchi Pharma America, Inc. 

S. 61 Paramus Road
Mack Centre IV, 4th Floor
Paramus  New Jersey  07652  U.S.A.
Phone: 201-291-2556 Fax: 201-909-3002


SEARCH JOBS


Industry
Pharmaceutical






Company News
Yamanouchi Pharmaceutical Co., Ltd. And Fujisawa Pharmaceutical Co., Ltd. Unite To Form Astellas Pharma Inc., North American Headquarters To Be In Chicago10/19/2005 5:13:11 PM
FDA Issues Approvable Letter For Yamanouchi Pharma America, Inc.'s Investigational Hyponatremia Treatment Conivaptan Hydrochloride Injection10/19/2005 5:12:19 PM
GlaxoSmithKline (GSK) And Yamanouchi Pharmaceutical Co., Ltd. Release: FDA Approves Vesicare(R) (Solifenacin Succinate) For The Treatment Of Overactive Bladder10/19/2005 5:12:15 PM
Yamanouchi Pharma America, Inc. Release: New Data From Two Studies Support Efficacy And Tolerability Of Vasopressin Receptor Antagonist Conivaptan Hydrochloride In Patients With Hyponatremia10/19/2005 5:12:01 PM
GlaxoSmithKline (GSK) And Yamanouchi Pharmaceutical Co., Ltd. Release: New Data Show Once-Daily Solifenacin Succinate Significantly Reduced Urgency Episodes For Patients With Overactive Bladder10/19/2005 5:11:21 PM
GlaxoSmithKline (GSK) And Yamanouchi Pharmaceutical Co., Ltd. Release: Once-Daily Solifenacin Succinate Improved Key Symptoms of Overactive Bladder In Women10/19/2005 5:11:11 PM
Astellas Pharma Inc. Release: Anti-Fungal Agent MYCAMINE(TM) Available To Physicians10/19/2005 5:10:11 PM
Yamanouchi Pharma America, Inc. Submits New Drug Application To The FDA For Conivaptan Hydrochloride To Treat Hyponatremia10/19/2005 5:09:52 PM
Yamanouchi Pharma America, Inc. Release: Study Shows Vasopressin Receptor Antagonist Conivaptan Hydrochloride Significantly Increased Serum Sodium Concentration In Patients With Hyponatremia10/19/2005 5:08:42 PM
//-->